Cetuximab — Drug Intelligence | 61 EU Trials

Filter these 61 trials by condition, phase, country and more.

Open in Search →

61 Registered trials

33 Recruiting

21 Completed trials

44 Sponsors

21 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 18 Phase II: 27 Phase I/II: 6 Phase IV: 2 Phase I (FiH): 8

Oversight events:

1 serious breach 7 temporary halts 3 urgent safety measures 2 unexpected events 13 corrective measures across 13 trials

View oversight register →

Indications tested

Colorectal cancer 6 Head and neck cancer 5 Colorectal cancer metastatic 4 Colorectal adenocarcinoma 2 Non-small cell lung cancer 1 Squamous cell carcinoma of head and neck 1 Adenocarcinoma of colon 1 Neoplasm malignant 1 Oropharyngeal cancer 1 Oral neoplasm 1 Head and neck cancer metastatic 1 Non-small cell lung cancer metastatic 1

Sponsors using this IMP

Gruppo Oncologico Dell'Italia Meridionale 4 Merck Sharp & Dohme LLC 4 Groupe Oncologie Radiotherapie Tete Cou 3 Pfizer Inc. 3 AstraZeneca AB 2 Charite Universitaetsmedizin Berlin KöR 2 Fondation Franc.Cancerologie Digestive 2 Fondazione GONO G.I. 2 IRCCS Istituto Nazionale Tumori Fondazione Pascale 2 Janssen - Cilag International 2 Universitair Medisch Centrum Groningen 2 Asociacion Grupo Tratamiento De Tumores Digestivos 1

All trials

61 total

Targeted fluorescence endoscopy for detection of the primary cancer lesion in patients with a metastasis of unknown primary tumor in the hea… Pending

2024-513897-23-00 Phase II 1 country Universitair Medisch Centrum Groningen
Phase 2, open-label, multicentre, single-arm study to evaluate the activity of the combination of EGFR inhibitors and c-MET inhibitors in pa… Pending

2024-518892-72-00 Phase II 1 country Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tum… Pending

2025-521209-42-00 Phase IV 3 countries Fondazione GONO G.I.
Fluorescence Intraoperative Surgical Margin Analysis in Head and Neck Cancer: Clinical Validation Pending

2025-522027-95-00 Phase III 1 country Universitair Medisch Centrum Groningen
Use of the chemotherapy FOLFIRI and cetuximab if given with treatment breaks or continuously in patients with newly diagnosed metastatic col… Pending

2025-522377-12-00 Phase III 1 country Charite Universitaetsmedizin Berlin KöR
A Study of S241656 in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies Pending

2025-523474-16-00 Phase I (FiH) 4 countries Institut De Recherches Internationales Servier IRIS
A clinical study of MK-1084 with other treatments for non-small cell lung cancer (MK-3475-01F) Recruiting

2024-512248-47-00 Phase I/II 6 countries Merck Sharp & Dohme LLC
A clinical study of new treatments for non-small cell lung cancer (MK-3475-01J) Recruiting

2025-521939-36-00 Phase II 5 countries Merck Sharp & Dohme LLC
A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c… Recruiting

2023-505606-42-00 Phase III 11 countries Aveo Pharmaceuticals Inc.
The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR… Recruiting

2024-512119-34-00 Phase II 12 countries Pfizer Inc.
ROMANCE Recruiting

2025-521319-38-00 Phase II 1 country Gruppo Oncologico Dell'Italia Meridionale
A Clinical Trial to learn about the effects of TLN-372 when given Alone and in Combination with Other Anti-Tumor Agents in people with Advan… Recruiting

2025-523086-22-00 Phase I (FiH) 1 country Treeline Biosciences Inc.
A Phase II Randomized Clinical Trial Comparing Two Cycles Versus Four Cycles of Combination Therapy with Cetuximab, Avelumab, Cisplatin, and… Recruiting

2025-521738-27-00 Phase II 1 country Charite Universitaetsmedizin Berlin KöR
A clinical study of MK-1084 in people with advanced solid tumors (MK 1084-014) Recruiting

2025-521737-91-00 Phase II 9 countries Merck Sharp & Dohme LLC
A clinical study of MK-1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK-1084-012). Recruiting

2024-517232-22-00 Phase III 9 countries Merck Sharp & Dohme LLC
Trial of an investigational drug after the rejection of an allogeneic transplant. Recruiting

2022-503063-15-00 Phase I (FiH) 1 country Fundacion Publica Andaluza para la Gestion de la Investigacion en Salud de Sevil…
A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting

2024-520386-31-00 Phase III 10 countries Johnson & Johnson Enterprise Innovation Inc.
CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected met… Recruiting

2024-519322-20-00 Phase III 2 countries Gruppo Oncologico Dell'Italia Meridionale
Systemic antitumor treatment with or without pressurized intraperitoneal aerosol chemotherapy (PIPAC) for colon peritoneal metastases – a mu… Recruiting

2024-514560-10-00 Phase II 1 country Institut De Cancerologie De L Ouest
Cetuximab With or Without Paclitaxel After Pembrolizumab-Chemotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck. Recruiting

2024-514953-31-00 Phase II 1 country Grupo Espanol De Tratamiento De Tumores De Cabeza Y Cuello
LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing st… Recruiting

2022-501315-13-00 Phase III 3 countries Centre Leon Berard
Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting

2024-513853-66-00 Phase III 10 countries Janssen Cilag International
A first-in-human, dose escalation and dose expansion study of SAR445877 in adult participants with advanced solid tumors Recruiting

2023-507141-28-00 Phase I (FiH) 2 countries Sanofi-Aventis Recherche & Developpement
A phase 3 study to evaluate petosemtamab vs. investigator's choice in previously treated metastatic / recurrent head and neck cancer. Recruiting

2023-510322-32-00 Phase III 12 countries Merus N.V.

Showing 1–24 of 61 trials

← All drugs A–Z